SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Myomo Inc (NYSEAmerican:MYO) reported the inclusion of six new orthotics and prosthetics sites to its Center of Excellence program, which identifies leading O&P practices that boost the MyoPro line of supported orthoses. The company is currently the sole lightweight wearable device that can assist restore function in the weakened or paralyzed hands and arms of people who have suffered a brachial plexus injury, stroke or other neuromuscular disability.

The details

With the orthosis, a paralyzed person can perform many activities of daily living counting feeding themselves, doing household tasks and carrying objects, and many can return to work. The inclusions to the Center of Excellence program come upon the firm’s footprint as it intends a presence in all the leading metropolitan areas in the United States. These comprise three new firms, as well as three new sites of Geauga Rehabilitation Engineering, an original Myomo CoE. The new sites are Loma Linda University Medical Center, Orthocraft, Cunningham Prosthetic Care and GRE locations in Cincinnati, OH, Detroit, MI and Columbus, OH.

Paul R. Gudonis, the CEO and Chairman of Myomo, expressed that they introduced their Center of Excellence plan in attempt to better advance O&P practices who have demonstrated a commitment to patient care by offering the MyoPro device. Brining these new practices to their Center of Excellence roster merely four months after introducing the program allows them to serve a growing number of patients across the nation who may be able to gain from the MyoPro orthosis.

Myomo CoEs contribute in joint marketing initiatives and receive patient support and training from Myomo. They also associate with therapists and physicians at major U.S. rehabilitation hospitals, who prescribe and recommend MyoPro and train new MyoPro users. Vince Baroni, the Clinical Director for GRE, expressed that their robust association with Myomo has turned into remarkable patient outcomes.

SHARE
Previous articleCan Advanced Micro Devices Inc (NASDAQ:AMD) Reverse Its Decline?
Next articleCarsmartt®, F/K/A Sport Supplement Group,Inc. (OTC:SRSP) is the new UBER and LYFT ?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.